Delpor, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2009-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.delpor.com
Clinical Trials
2
Active:0
Completed:2
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)Safety, Tolerability, and Pharmacokinetics of Naltrexone Implant (DLP-160)
Phase 1
Completed
- Conditions
- Opiod Use Disorder
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- Delpor, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT05304364
- Locations
- 🇦🇺
CMAX, Adelaide, South Australia, Australia
Safety, Tolerability, and Pharmacokinetics of Switching From Oral Risperidone to Risperidone Implant
Phase 1
Completed
- Conditions
- Schizophrenia
- First Posted Date
- 2020-06-05
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Delpor, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT04418466
- Locations
- 🇺🇸
Collaborative Neuroscience Research, Long Beach, California, United States
🇺🇸Segal Trials, Miami Lakes, Florida, United States
News
No news found